AR094919A1 - Usos terapéuticos para anticuerpos vegfr1 - Google Patents
Usos terapéuticos para anticuerpos vegfr1Info
- Publication number
- AR094919A1 AR094919A1 ARP140100630A ARP140100630A AR094919A1 AR 094919 A1 AR094919 A1 AR 094919A1 AR P140100630 A ARP140100630 A AR P140100630A AR P140100630 A ARP140100630 A AR P140100630A AR 094919 A1 AR094919 A1 AR 094919A1
- Authority
- AR
- Argentina
- Prior art keywords
- vegfr1
- antibodies
- therapeutic uses
- less
- vegfr1 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
La presente se refiere a métodos de uso de anticuerpos VEGFR1 (receptor del factor de crecimiento vascular endotelial) para el tratamiento de la enfermedad renal crónica, así como anticuerpos VEGFR1. Reivindicación 11: El método de conformidad con cualquiera de las reivindicaciones 1 - 10, caracterizado porque el anticuerpo VEGFR¹ tiene una KD para VEGFR1 de menos de 80 pM como se determina por resonancia de plasmón superficial. Reivindicación 12: El método de conformidad con cualquiera de las reivindicaciones 1 - 11, caracterizado porque el anticuerpo VEGFR1 neutraliza la unión de VEGF-A in vitro a VEGFR1 con una IC₅₀ de menos de 2.0 nM.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788870P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094919A1 true AR094919A1 (es) | 2015-09-09 |
Family
ID=50680115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100630A AR094919A1 (es) | 2013-03-15 | 2014-02-27 | Usos terapéuticos para anticuerpos vegfr1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9670284B2 (es) |
| EP (1) | EP2970480A1 (es) |
| JP (1) | JP2017125013A (es) |
| KR (1) | KR20150119161A (es) |
| CN (1) | CN105102481A (es) |
| AR (1) | AR094919A1 (es) |
| AU (1) | AU2014237300B2 (es) |
| BR (1) | BR112015020199A2 (es) |
| CA (1) | CA2901509A1 (es) |
| EA (1) | EA201591513A1 (es) |
| HK (1) | HK1212713A1 (es) |
| IL (1) | IL241434A0 (es) |
| MX (1) | MX2015013066A (es) |
| SG (1) | SG11201507674UA (es) |
| TW (1) | TW201517916A (es) |
| WO (1) | WO2014150314A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41094A (fr) | 2014-12-02 | 2017-10-10 | Lilly Co Eli | Procédés de traitement de troubles rénaux |
| EP3783031B1 (en) | 2014-12-03 | 2023-08-02 | Aimed Bio Inc. | Antibody against neuropilin 1 and use thereof |
| MA41375A (fr) | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| EP3280737B1 (en) | 2015-04-07 | 2022-03-09 | Takeda Pharmaceutical Company Limited | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
| MA41899A (fr) * | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
| CN107683143A (zh) | 2015-04-07 | 2018-02-09 | 夏尔人类遗传性治疗公司 | 治疗支气管肺发育不良的抗flt‑1抗体 |
| KR101993893B1 (ko) | 2016-06-03 | 2019-07-01 | 사회복지법인 삼성생명공익재단 | 항-nrp1 항체 스크리닝 방법 |
| IL310840A (en) * | 2021-08-16 | 2024-04-01 | Janssen Biotech Inc | Anti-VEGFR1 antibodies and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101102791B (zh) | 2004-11-18 | 2011-12-14 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| AU2011268458B2 (en) * | 2010-06-15 | 2014-06-12 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
-
2014
- 2014-02-26 TW TW103106577A patent/TW201517916A/zh unknown
- 2014-02-27 AR ARP140100630A patent/AR094919A1/es unknown
- 2014-03-11 AU AU2014237300A patent/AU2014237300B2/en not_active Ceased
- 2014-03-11 CN CN201480014740.9A patent/CN105102481A/zh active Pending
- 2014-03-11 CA CA2901509A patent/CA2901509A1/en not_active Abandoned
- 2014-03-11 US US14/203,675 patent/US9670284B2/en not_active Expired - Fee Related
- 2014-03-11 EA EA201591513A patent/EA201591513A1/ru unknown
- 2014-03-11 EP EP14722408.3A patent/EP2970480A1/en not_active Withdrawn
- 2014-03-11 BR BR112015020199A patent/BR112015020199A2/pt active Search and Examination
- 2014-03-11 WO PCT/US2014/022925 patent/WO2014150314A1/en active Application Filing
- 2014-03-11 SG SG11201507674UA patent/SG11201507674UA/en unknown
- 2014-03-11 KR KR1020157024802A patent/KR20150119161A/ko active IP Right Grant
- 2014-03-11 MX MX2015013066A patent/MX2015013066A/es unknown
-
2015
- 2015-09-10 IL IL241434A patent/IL241434A0/en unknown
-
2016
- 2016-01-21 HK HK16100631.7A patent/HK1212713A1/zh unknown
-
2017
- 2017-01-06 JP JP2017000925A patent/JP2017125013A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| HK1212713A1 (zh) | 2016-06-17 |
| WO2014150314A1 (en) | 2014-09-25 |
| CA2901509A1 (en) | 2014-09-25 |
| MX2015013066A (es) | 2016-09-21 |
| JP6140841B2 (ja) | 2017-05-31 |
| BR112015020199A2 (pt) | 2017-10-10 |
| IL241434A0 (en) | 2015-11-30 |
| SG11201507674UA (en) | 2015-10-29 |
| EP2970480A1 (en) | 2016-01-20 |
| US9670284B2 (en) | 2017-06-06 |
| US20140271675A1 (en) | 2014-09-18 |
| JP2016511758A (ja) | 2016-04-21 |
| CN105102481A (zh) | 2015-11-25 |
| JP2017125013A (ja) | 2017-07-20 |
| KR20150119161A (ko) | 2015-10-23 |
| EA201591513A1 (ru) | 2016-01-29 |
| TW201517916A (zh) | 2015-05-16 |
| AU2014237300B2 (en) | 2017-06-01 |
| AU2014237300A1 (en) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094919A1 (es) | Usos terapéuticos para anticuerpos vegfr1 | |
| CY1119055T1 (el) | Αντισωματα που προσδενονται στην il-17a και στην il-17f | |
| CU20150128A7 (es) | Conjugados fármaco-anticuerpo | |
| CL2015003117A1 (es) | Modificaciones en la estructura cristalina | |
| EA201300978A1 (ru) | Антитела к сеа | |
| CL2015002357A1 (es) | Nuevos conjugados de anticuerpos y usos de los mismos | |
| UY35399A (es) | Conjugados de fármacos con anticuerpos | |
| AR094896A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| EA201592269A1 (ru) | Способы и композиции для снижения иммуносупрессии опухолевыми клетками | |
| CL2014001640A1 (es) | Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo. | |
| DK2953976T3 (da) | Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater | |
| UY35044A (es) | ANTICUERPOS ANTI-dDr1 | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| SG10201808738WA (en) | Fusokines involving cytokines with strongly reduced receptor binding affinities | |
| CR20130598A (es) | Composiciones de nucleasa terapéuticas y métodos | |
| ECSP14026138A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| AR094403A1 (es) | Terapia de combinación de anticuerpos anti-her3 | |
| ES2572215T3 (es) | Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico | |
| BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
| MX2015010429A (es) | Cetuximab con glicosilación modificada y sus usos. | |
| DOP2018000019A (es) | Inmunoconjugados de il22 | |
| MX2016006743A (es) | Ensayo de puente a base de resonancia de plasmon superficial para determinar la actividad biologica de moleculas multiespecificas multivalentes. | |
| BR112019001409A2 (pt) | células renais bioativas para o tratamento de doença renal crônica | |
| PH12015500890A1 (en) | Vaccine for preventing porcine edema disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |